Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01409434 · ClinicalTrials.gov registry record · Phase 4
Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT01409434 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 44 participants.
The verdict
NCT01409434, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a research study of the long term effects on blood sugar and cholesterol of blood pressure lowering medications. People are invited to participate in this research study if they participated in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR 1, NCT00246519 or PEAR 2, NCT01203852) study and are still taking a thiazide diuretic. In PEAR, the effects on blood pressure, blood sugar, and cholesterol of the high blood pressure drugs hydrochlorothiazide and atenolol over an 18 week period were evaluated. This PEAR follow-up study will determine the effects of thiazide diuretics on blood sugar and cholesterol, but in the period since the PEAR trial. The study hypothesis is that long term exposure to thiazide diuretics results in larger increases in blood sugar and cholesterol levels than short term exposure.
Interventions
- DRUG Oral Glucose Tolerance Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01409434
The ClinicalTrials.gov registry entry for NCT01409434 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral Glucose Tolerance Test is the first listed.
NCT01409434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01409434 about?
NCT01409434 is a clinical study titled "Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study". This is a research study of the long term effects on blood sugar and cholesterol of blood pressure lowering medications. People are invited to participate in this research study if they participated in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR 1, NCT00246519 or PEAR 2, NCT01...
What is the current status of trial NCT01409434?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2010-06. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01409434?
The interventions under investigation include: Oral Glucose Tolerance Test (DRUG).
Who is sponsoring clinical trial NCT01409434?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.